These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2212750)

  • 21. Type-specific efficacy of acellular pertussis vaccine.
    Aoyama T; Murase Y; Gonda T; Iwata T
    Am J Dis Child; 1988 Jan; 142(1):40-2. PubMed ID: 2893537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical studies on efficacy and safety of an acellular pertussis vaccine in Aichi Prefecture, Japan.
    Isomura S
    Dev Biol Stand; 1991; 73():37-42. PubMed ID: 1778331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand.
    Koepke R; Eickhoff JC; Ayele RA; Petit AB; Schauer SL; Hopfensperger DJ; Conway JH; Davis JP
    J Infect Dis; 2014 Sep; 210(6):942-53. PubMed ID: 24903664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine.
    Stehr K; Cherry JD
    Dev Biol Stand; 1997; 89():58-62. PubMed ID: 9333571
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy of whole-cell pertussis vaccine in preschool children in the United States.
    Onorato IM; Wassilak SG; Meade B
    JAMA; 1992 May; 267(20):2745-9. PubMed ID: 1578592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outbreak of pertussis in a residential facility for handicapped people.
    Tanaka Y; Fujinaga K; Goto A; Iwai H; Aoyama T; Murase Y; Iwata T
    Dev Biol Stand; 1991; 73():329-32. PubMed ID: 1838084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of acellular pertussis vaccine in early childhood after household exposure.
    Schmitt HJ; von König CH; Neiss A; Bogaerts H; Bock HL; Schulte-Wissermann H; Gahr M; Schult R; Folkens JU; Rauh W; Clemens R
    JAMA; 1996 Jan; 275(1):37-41. PubMed ID: 8531284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absolute efficacy of acellular pertussis vaccines in household settings.
    Storsaeter J; Gustafsson L
    Dev Biol Stand; 1997; 89():153-9. PubMed ID: 9272345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age.
    Halperin SA; Mills E; Barreto L; Pim C; Eastwood BJ
    Pediatr Infect Dis J; 1995 Sep; 14(9):792-7. PubMed ID: 8559630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acellular vaccines for preventing whooping cough in children.
    Zhang L; Prietsch SO; Axelsson I; Halperin SA
    Cochrane Database Syst Rev; 2011 Jan; (1):CD001478. PubMed ID: 21249646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine.
    Lugauer S; Heininger U; Cherry JD; Stehr K
    Eur J Pediatr; 2002 Mar; 161(3):142-6. PubMed ID: 11998910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials.
    Cherry JD
    Pediatr Infect Dis J; 1997 Apr; 16(4 Suppl):S90-6. PubMed ID: 9109163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial.
    Cherry JD; Heininger U; Stehr K; Christenson P
    Pediatrics; 1998 Oct; 102(4 Pt 1):909-12. PubMed ID: 9755264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.
    Patel SS; Wagstaff AJ
    Drugs; 1996 Aug; 52(2):254-75. PubMed ID: 8841742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-response to acellular pertussis vaccine and comparison with whole cell pertussis vaccine at 15-24 months and 4-6 years of age. Acellular Pertussis Vaccine Study Team.
    Auerbach BS; Wilson ME; Lake AM; Deforest A; Steinhoff M; Halsey NA
    Vaccine; 1992; 10(1):14-20. PubMed ID: 1539456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.